NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 230 filers reported holding NEKTAR THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $13,859 | -96.8% | 24,095 | -96.1% | 0.00% | -100.0% |
| Q1 2023 | $432,211 | -55.7% | 614,897 | +42.4% | 0.01% | -56.7% |
| Q4 2022 | $976,087 | -5.9% | 431,897 | +33.2% | 0.03% | -26.8% |
| Q3 2022 | $1,037,000 | +6.8% | 324,356 | +26.8% | 0.04% | +5.1% |
| Q2 2022 | $971,000 | +61.3% | 255,771 | +128.7% | 0.04% | +85.7% |
| Q1 2022 | $602,000 | – | 111,823 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |